MAST

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024
HER2, CD8, Phosphorylation, Survival, Cholangiocarcinoma, Immunotherapy, RECIST, Oncology, MAST, Patient, City, Degranulation, ASX, ADCC, Cancer, Hope, Overalls, Pembrolizumab, PRS, AACR, SPECT, Vaccination, Melanoma, Recurrence, PD-L1, IMU, Medical imaging

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.

Key Points: 
  • Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.
  • SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
  • HER-Vaxx induced HER2-specific antibodies able to mediate antibody-dependent cell cytotoxicity (ADCC) and inhibit intracellular HER2 phosphorylation and correlated with tumour reduction.
  • The HER-Vaxx induced HER2-specific antibodies demonstrate a similar mechanism of action to HERCEPTINâ validating B cell immunotherapy as an alternative anti-cancer agent to monoclonal antibodies.

BEVM Bitcoin Layer2 Closes Seed Round with RockTree Capital, Sathoshi Lab & 20 Others

Retrieved on: 
Wednesday, March 27, 2024
Consensus, EVM, MAST, Consensus decision-making, Capital, Financial regulation, Architecture, DBFX, BTC, Ecosystem, Traction, Safety, Geography, Cryptocurrency

Singapore, Singapore, March 27, 2024 (GLOBE NEWSWIRE) -- The Bitcoin Layer2 project BEVM has announced the completion of its seed round, and also a part of its Series A round, raising tens of million USD.

Key Points: 
  • Singapore, Singapore, March 27, 2024 (GLOBE NEWSWIRE) -- The Bitcoin Layer2 project BEVM has announced the completion of its seed round, and also a part of its Series A round, raising tens of million USD.
  • BEVM is the first EVM-compatible Bitcoin Layer2 network built on Taproot Consensus and uses $BTC as gas, aiming to bring 10% of $BTC into its Layer2 network environment.
  • Gavin Guo, Core Builder of BEVM said “Taproot Consensus is the final result of our team’s six years of exploring Bitcoin Layer2 solutions.
  • BEVM is currently the most decentralized and secure BTC layer2 solution.”
    BEVM has already implemented decentralized Bitcoin cross-chain custody services through Schnorr Signature, MAST and Bitcoin SPVs.

Agilent Brings Great Science to Life at Analytica 2024

Retrieved on: 
Thursday, April 4, 2024
Technology, Chemicals, Plastics, Health, Manufacturing, Batteries, Alternative Energy, Energy, Machinery, Research, Software, Health Technology, Hardware, Science, Semiconductor, Online, Immersion, Automation, Sustainable energy, Advanced Materials, Biotechnology, PFAS, Bioreactor, Environment, Biophysical environment, ICP-OES, MAST, Tissue, Food, ADS, Molecular biology, Laboratory, ICP-MS, Merck Group, Workflow, Agilent Technologies, Water, Chemical substance, BioTek, Fine chemical

Agilent Technologies Inc. (NYSE: A) today announced its participation in Analytica 2024, where it will unveil its latest innovations and transformative workflows.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced its participation in Analytica 2024, where it will unveil its latest innovations and transformative workflows.
  • Analytica, the premier international trade fair for laboratory technology, analysis, and biotechnology, is scheduled to take place from April 9 to 12 in Munich, Germany.
  • Agilent technical experts will be available to share insights into these latest innovations and intuitive workflows.
  • Join us as we bring Great Science to Life!

Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

Retrieved on: 
Thursday, February 22, 2024
Allotransplantation, Skin cancer, Cholangiocarcinoma, Fast track (FDA), NHL, Melanoma, FDA, Pembrolizumab, CD19, Rupture, Lung, Epidemiology, Breast, Safety, Neoplasm, ASX, Bone marrow, Patient, RECIST, MAST, National library, IMU, Blinatumomab, DLBCL, Cancer, BTC, Vaccine

Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.

Key Points: 
  • Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.
  • Notably, in our Phase 1 MAST CF33 oncolytic virus trial, we’ve seen encouraging response rates during dose escalation, including one complete response in a patient with cholangiocarcinoma, and two partial responses in melanoma as we continue to dose escalate with no safety issues.
  • Importantly, two out of three of these responses were achieved with CF33 monotherapy.
  • onCARlytics uses an antigen/target-armed CF33, followed by treatment with a CD19 targeting therapy directed against that antigen or target.

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Retrieved on: 
Wednesday, November 22, 2023
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, American Cancer Society, PSA, Disease, Urology, Patient, Prostate cancer, MAST, Neoplasm, Prostate-specific antigen, Physician, SUO, Society, Biopsy, Medical imaging, Lace

Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.
  • Collectively, the posters will report data from more than 60,000 patients.
  • The American Cancer Society estimates that there will be nearly 290,000 new cases of prostate cancer in the U.S. this year.
  • An ongoing challenge in the management of prostate cancer is distinguishing between patients whose tumors require careful monitoring, known as active surveillance, and those who require intervention.

Mobile Application Security Testing Market worth $3.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, December 14, 2023
Cloud, Data management, Acquisition, Research, IPad, Organization, Software, Privacy, IPod Touch, IBM, Knowledge, OpenText, Intellectual property, NowSecure, MAST, CE, API, HCL, Growth, App Store (iOS/iPadOS), OS, IOS, IPhone, MEA, Fintech, Architecture, Mobile phone, Retail, Medical device, Online shopping, Risk management, Mobile, Apple, Apptio

Mobile application security testing adoption in large organizations has witnessed a notable upward trend in recent years.

Key Points: 
  • Mobile application security testing adoption in large organizations has witnessed a notable upward trend in recent years.
  • Large organizations are investing in robust mobile application security testing practices to identify and mitigate vulnerabilities proactively.
  • Top Key Companies in Mobile Application Security Testing Market:
    August 2023 - Synopsys announced two new collaboration agreements with NowSecure, recognized experts in mobile security and privacy, and Secure Code Warrior, provider of the leading agile learning platform for developer-driven security, to expand its Software Integrity Group's industry-leading portfolio of application security testing (AST) solutions.
  • Mobile Application Security Testing Market Advantages:
    MAST aids in locating holes and weak points in the architecture, design, and coding of mobile applications.

Mobile Application Security Testing Market worth $3.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, December 14, 2023
Cloud, Data management, Acquisition, Research, IPad, Organization, Software, Privacy, IPod Touch, IBM, Knowledge, OpenText, Intellectual property, NowSecure, MAST, CE, API, HCL, Growth, App Store (iOS/iPadOS), OS, IOS, IPhone, MEA, Fintech, Architecture, Mobile phone, Retail, Medical device, Online shopping, Risk management, Mobile, Apple, Apptio

Mobile application security testing adoption in large organizations has witnessed a notable upward trend in recent years.

Key Points: 
  • Mobile application security testing adoption in large organizations has witnessed a notable upward trend in recent years.
  • Large organizations are investing in robust mobile application security testing practices to identify and mitigate vulnerabilities proactively.
  • Top Key Companies in Mobile Application Security Testing Market:
    August 2023 - Synopsys announced two new collaboration agreements with NowSecure, recognized experts in mobile security and privacy, and Secure Code Warrior, provider of the leading agile learning platform for developer-driven security, to expand its Software Integrity Group's industry-leading portfolio of application security testing (AST) solutions.
  • Mobile Application Security Testing Market Advantages:
    MAST aids in locating holes and weak points in the architecture, design, and coding of mobile applications.

Software Vulnerabilities Are on the Decline, According to New Synopsys Research

Retrieved on: 
Tuesday, November 14, 2023
Business Integration Group, Inc., Organization, Software, Synopsys, Risk, Running, MAST, Cross, App Store (iOS/iPadOS), SNPS, DAST, Quilon Aerodrome, SCA, SAST, Medical device

SUNNYVALE, Calif., Nov. 14, 2023 /PRNewswire/ -- Synopsys, Inc. (Nasdaq: SNPS) today published the 2023 Software Vulnerability Snapshot report. According to the data, analyzed by Synopsys Cybersecurity Research Center (CyRC), there has been a significant decrease in vulnerabilities found in target applications – from 97% in 2020 to 83% in 2022 – an encouraging sign that code reviews, automated testing and continuous integration are helping to reduce common programming errors.

Key Points: 
  • SUNNYVALE, Calif., Nov. 14, 2023 /PRNewswire/ -- Synopsys, Inc. (Nasdaq: SNPS ) today published the 2023 Software Vulnerability Snapshot report .
  • For example, server misconfigurations represented an average of 18% of the total vulnerabilities found in the three years of tests.
  • However, only 27% of those tests contained high-severity vulnerabilities, and 6.2% contained critical-severity vulnerabilities.
  • Software is likely vulnerable if you do not know the versions of all components in use, including third-party and open source components.

Approved Montana Field-Testing Flexibility Waiver Empowers Students and Educators

Retrieved on: 
Tuesday, August 22, 2023
Parent, United States Department of Education, MAST, Montana State University, State, Student, Public, Partnership, Montana Office of Public Instruction, Office of Inspector General, U.S. Department of Health and Human Services, Child, Pharmaceutical industry, Tutoring

AUSTIN, Texas , Aug. 22, 2023 /PRNewswire/ -- The U.S. Department of Education (USED) has approved a Field-Testing Flexibility Waiver for the new Montana Alternative Student Testing (MAST) pilot program, an innovative through-year assessment design championed by Montana State Superintendent Elsie Arntzen.

Key Points: 
  • AUSTIN, Texas , Aug. 22, 2023 /PRNewswire/ -- The U.S. Department of Education (USED) has approved a Field-Testing Flexibility Waiver for the new Montana Alternative Student Testing (MAST) pilot program, an innovative through-year assessment design championed by Montana State Superintendent Elsie Arntzen.
  • The waiver approval will enable students, teachers, and administrators participating in the pilot this year to take the alternative assessment without having to also take the current state summative assessment.
  • State Superintendent Arntzen celebrated the decision: "The approval of the Field-Testing Flexibility Waiver marks a significant milestone for Montana students and educators.
  • The Montana Office of Public Instruction website provides more information about Montana's Field-Testing Flexibility Waiver and the innovative MAST pilot program.

Kondukto announces AI Remediation and support for eShard MAST

Retrieved on: 
Tuesday, August 8, 2023
Software, Networks, Internet, Artificial Intelligence, Technology, Apps, Applications, Mobile, Wireless, Security, Software as a service, ASPM, ChatGPT, MAST, App Store (iOS/iPadOS), Application, Machine learning, Artificial intelligence, Knowledge, ASOC, Automation, Satellite navigation device, Medical device

Today Kondukto Inc., the leading Application Security Orchestration & Correlation (ASOC) platform for cloud and on-premise workloads, announces the availability of its innovative AI Remediation feature.

Key Points: 
  • Today Kondukto Inc., the leading Application Security Orchestration & Correlation (ASOC) platform for cloud and on-premise workloads, announces the availability of its innovative AI Remediation feature.
  • Our AI Remediation feature will cut down time-to-remediation and increase team productivity across the board.”
    Modern AI technologies like ChatGPT have demonstrated to be capable of taking automation tasks to a new level.
  • Kondukto’s AI Remediation feature uses these machine learning techniques to automate the remediation of identified vulnerabilities across scanner technologies and applications.
  • The new AI Remediation feature is part of the Autumn 2023 release of the Kondukto Platform and will be available to all customers worldwide, both SaaS and on-premise.